Immunology Product Guide » Anti-Inflammatory

NicOx submits naproxcinod for FDA approval

Jim Marino — Wed, 07 Oct 2009 02:24:47 +0000

French biotech firm NicOx has submitted a new drug application (NDA) to the US regulatory authority for its anti-inflammatory drug naproxcinod. The naproxcinod drug is developed for the treatment of osteoarthritis. The marketing approval of the drug could deal a blow to sales of the Pfizer medicine Celebrex. The company also plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in the fourth quarter of 2009.

Glenmark Alcometasone Dipropionate ointment approved

Jim Marino — Wed, 19 Aug 2009 08:03:49 +0000

Glenmark Generics Limited has received ANDA approval from the FDA for Alcometasone Dipropionate Ointment, 0.05%. Alcometasone Dipropionate ointment is a low to medium potency corticosteroid indicated for the relief of the inflammatory and manifestations of corticosteroid- responsive dermatoses. The company will commence marketing and distribution of this product in the US market immediately.

Pycnogenol inhibits production of enzymes involved with inflammation

Jim Marino — Wed, 29 Jul 2009 05:25:14 +0000

A recent study published in International Immunopharmacology reveals Pycnogenol® (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, inhibits the generation of COX-2 and 5-LOX, two naturally occurring enzymes associated with a host of inflammatory conditions. By shutting down the production of these enzymes involved with inflammation, Pycnogenol can actually decrease pain and reduce inflammatory conditions.

Anti-inflammatory drugs might treat resistant cancer

Jim Marino — Wed, 15 Jul 2009 04:28:28 +0000

According to a study conducted by researchers from University of California, the Burnham Institute for Medical Research and the University of Copenhagen Hospital, anti-inflammatory drugs that are already in the market for the treatment of arthritis are also effective in treating a chemotherapy-resistant form of lymphoma. The research focused on a type of non-Hodgkin lymphoma called diffuse large B-cell lymphoma discovered that anti-inflammatory drugs, etanercept and infliximab, used for arthritis shrank lymphoma tumors in mice.